Gary S. Balkema - 22 Feb 2022 Form 4 Insider Report for PLx Pharma Inc. (PLXPQ)

Role
Director
Signature
/s/ Natasha Giordano, as Attorney-in-Fact
Issuer symbol
PLXPQ
Transactions as of
22 Feb 2022
Net transactions value
$0
Form type
4
Filing time
24 Feb 2022, 19:10:23 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLXPQ Stock Option (right to buy) Award $0 +20,000 $0.000000 20,000 22 Feb 2022 Common Stock 20,000 $4.99 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan, as amended.
F2 These stock options vest in full on the first anniversary of the grant date.